Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
X6632
- Development stage
- Preclinical
- Lead developer
- Universitat Heidelberg
- Modality
- Small Molecules
01
Overview
X6632 is a coumarin-derived small molecule pan-inhibitor of DNA binding (ID) proteins. It acts as a second-generation ID antagonist with dual activity, targeting both cancer cells and the tumor-supporting microvasculature. Developed by Heidelberg University and the Karlsruhe Institute of Technology, X6632 suppresses the expression of ID proteins, inhibiting tumor cell proliferation, migration, and invasion, as well as disrupting endothelial cell functions and angiogenesis. In preclinical models, X6632 has demonstrated efficacy against melanoma, triple-negative breast cancer, and lung cancer, showing enhanced therapeutic outcomes when combined with immune checkpoint inhibitors.
- Other names
- coumarin derivative X6632
02
Targets
ID1 (Inhibitor of DNA binding protein 1)ID3 (Inhibitor of DNA binding protein 3)ID4 (DNA-binding protein inhibitor 4)
Beyond the preview
Go deeper on X6632.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on X6632.